CLINICAL STUDIES

PRIORITIZE HF

Phase IIb, international, multicenter, parallel group, randomized, double-blind, placebo- controlled study in patients with chronic heart failure (NYHA II-IV), evaluating the benefits and risks of using sodium zirconium cyclosilicate (ZS) to initiate and intensify RAAS blocker therapy

Study Phase:

Phase 2

Criteria:

  • Male or Female 18 years or older
  • Heart Failure or Ejection Fraction (NYHA functional class II-IV) present for at least 3 months.
  • Left Ventricular Ejection Fraction ≤ 40% (Any measurement made within the past 12 month)
Register